Literature DB >> 9875192

How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data.

E Epstein1.   

Abstract

OBJECTIVE: To analyze studies on oral treatment of toenail onychomycosis so as to aid clinicians and patients in making informed decisions. DATA SOURCES: Studies dealing with treatment of toenail onychomycosis were identified by means of 2 MEDLINE search strategies. One was a title search using the word "toenail"; the other search used the combined Medical Subject Headings "onychomycosis" and "therapy". STUDY SELECTION: Articles were read to ascertain that they (1) described results in toenails, (2) used both culture and microscopy, and (3) included a clinical evaluation. Not included were case reports, series of fewer than 15 subjects, reports that combined fingernail onychomycosis and toenail onychomycosis in their statistics, and articles reporting only the total number of toenails cured without providing data as to how many subjects were cured. DATA EXTRACTION: This elimination process left 26 articles, which were then analyzed by means of a checklist that included a morphologically normal nail, mycological findings, and methodological items including recurrence rate, intent-to-treat analysis, placebo group, and whether terms were defined. DATA SYNTHESIS: When there was sufficient data, the frequency with which the treatment achieved normal mycological results, a clinically normal nail, and a disease-free nail (normal-appearing nail plus normal mycological results) was calculated. Confidence intervals were calculated for disease-free nail results.
CONCLUSIONS: Standard courses of terbinafine achieved a disease-free nail in approximately 35% to 50% of patients. For itraconazole, the relevant disease-free nail rate was about 25% to 40%. Disease reappearance is an important issue; unfortunately data are lacking as to its frequency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875192     DOI: 10.1001/archderm.134.12.1551

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  11 in total

1.  Treatment of toenail onychomycosis. Will Paper's key message soon appear in promotional material for drug?

Authors:  F Kavalier
Journal:  BMJ       Date:  1999-10-30

2.  VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.

Authors:  E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; L Long; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

Review 3.  Onychomycosis in the elderly : drug treatment options.

Authors:  Daniel S Loo
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 4.  Onychomycosis nailed.

Authors:  M Leelavathi; Mn Noorlaily
Journal:  Malays Fam Physician       Date:  2014-04-30

5.  Comparison of diagnostic methods in the evaluation of onychomycosis.

Authors:  Iman Haghani; Tahereh Shokohi; Zohreh Hajheidari; Alireza Khalilian; Seyed Reza Aghili
Journal:  Mycopathologia       Date:  2013-02-01       Impact factor: 2.574

Review 6.  The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

7.  [Onychomycosis].

Authors:  D Reinel
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

8.  Onychomycosis of Toenails and Post-hoc Analyses with Efinaconazole 10% Solution Once-daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

9.  Efinaconazole Topical Solution, 10%, for the Treatment of Mild and Moderate Toenail Onychomycosis.

Authors:  David A Rodriguez
Journal:  J Clin Aesthet Dermatol       Date:  2015-06

10.  Excellent Response of Dermatophytoma and Nail Splitting to Nail Plate Debridement Plus Topical Ciclopirox Olamine 1% Solution.

Authors:  Hamed Mohamed Abdo
Journal:  Skin Appendage Disord       Date:  2020-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.